Evaluation of the cyclooxygenase selectivity of robenacoxib and its effect on recovery of ischemia-injured jejunal mucosa in horses.

This study is about the examination of a drug called robenacoxib and its impact on the recovery of jejunal tissue, part of the small intestine, in horses after ischemic injury. The study also investigates how selectively the drug acts on the enzymes COX-1 and COX-2, which play roles in inflammation.

Experiment Structure

• To test the selectivity of robenacoxib toward two enzymes (COX-1 and COX-2), blood samples from six horses were collected.
• The degree of activity inhibition of the enzymes was measured, and from this, the selectivity of robenacoxib was calculated.
• To analyze the effect of robenacoxib on healing, a second group of six horses underwent a procedure to cause ischemic injury to the jejunum, a section of small intestine.
• Ischemia-injured tissues and control tissues were then treated with either a control solution (Ringer’s solution), another nonsteroidal anti-inflammatory drug flunixin meglumine, or robenacoxib.
• Over a period of four hours, the researchers measured transepithelial electrical resistance and mannitol flux, two indicators of intestinal recovery and function. Additionally, the researchers analyzed the concentrations of certain metabolites (TXB2 and prostaglandin E) in the bathing solutions to assess the function of the enzymes COX-1 and COX-2.

Results

• The findings indicated that robenacoxib had greater selectivity for COX-2, with a COX selectivity ratio of 61.01.
• Ischemia-injured tissues treated with flunixin meglumine had significantly lower transepithelial electrical resistance (a measure of barrier function) compared to robenacoxib-treated and control tissues, suggesting that robenacoxib may better help to maintain barrier function during recovery.
• There was a significant increase in the concentrations of TXB2 and prostaglandin E metabolites in both control and robenacoxib-treated tissues, but not in flunixin meglumine-treated tissues. This result further demonstrates the stronger inhibitory effect of flunixin meglumine on COX-2.
• In turn, these findings provide evidence of robenacoxib’s selective inhibition on COX-2 and its positive influence on the recovery of barrier function in the ischemia-injured equine jejunal tissue.

Conclusion

• In conclusion, the study suggests that robenacoxib may be better suited for horses to recover from intestinal ischemic injuries due to its selectivity for COX-2 and its influence on barrier recovery function.